WO2012075908A1 - 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途 - Google Patents
一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途 Download PDFInfo
- Publication number
- WO2012075908A1 WO2012075908A1 PCT/CN2011/083357 CN2011083357W WO2012075908A1 WO 2012075908 A1 WO2012075908 A1 WO 2012075908A1 CN 2011083357 W CN2011083357 W CN 2011083357W WO 2012075908 A1 WO2012075908 A1 WO 2012075908A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- virus
- unsubstituted
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention belongs to the field of pharmacy.
- the invention relates to the medical use of a class of compounds having a 2,4-diaminoquinazoline as a skeleton, and more particularly to a 2,4-diaminoquinazoline compound in the treatment of a disease caused by a Flaviviridae virus Use, especially for the use of such compounds in anti-hepatitis C virus and anti-dengue viruses. Background technique
- the virus is the smallest pathogenic microorganism.
- the virus-infected disease has become one of the major diseases that threaten human health. It has the characteristics of high incidence, rapid spread, widespread popularity and large variability.
- Flaviviridae includes three virus genus, ⁇ flavivirus, pestivirus, and hepacivirus, with more than 60 viruses.
- Dengue fever virus (DV) belongs to the flavivirus and flavivirus positive-strand RNA viruses and has four serotypes.
- Classical dengue fever (DF) and dengue henorrhagic fever/Dengue Shock Syndrome (DHF/DSS) caused by mosquito transmission are acute infectious diseases, and their pathogens can cause A variety of diseases in the human body can cause death in severe cases. The disease is widely distributed. In recent years, DF cases are increasing rapidly.
- Hepatitis C virus belongs to the family Flaviviridae, a genus of hepatitis virus, which is a single positive-strand RNA virus, and the virus particles are spherical.
- HCV Hepatitis C virus
- hepatitis C virus was identified as the pathogen HCV of non-A, non-B hepatitis after transfusion, which can cause a variety of clinical symptoms, mostly benign or subacute. Many patients show symptoms of chronic liver damage until 10-30 years after infection.
- Another object of the present invention is to provide a pharmaceutical composition for treating diseases caused by Flaviviridae viruses, particularly a pharmaceutical composition for treating dengue virus and hepatitis C virus.
- the present invention provides a quinazoline compound represented by the following formula I or a physiologically acceptable salt thereof for the preparation of an anti-flavivir virus, in particular It is used in anti-hepatitis C virus and dengue virus drugs: among them,
- the substituted substituent is selected from the group consisting of a C1-C10 alkyl group, a C1-C10 alkoxy group, a halogen, a hydroxyl group, a nitro group, a carboxyl group, a C6-C10 aromatic hydrocarbon group, a phenol group, an amino group, a C1-C10 hydrocarbon group-substituted amine group, Heterocyclic group and trifluoromethyl group;
- the heterocyclic group is a 3- to 7-membered monocyclic or 8- to 10-membered bicyclic ring containing 1-3 hetero atoms selected from N, 0 and S.
- the quinazoline compound of the present invention is most preferably selected from the following quinazoline compounds:
- the quinazoline compound of the present invention can be synthesized by the following synthesis method:
- Step (1) a compound of the formula ⁇ is obtained by a nucleophilic substitution reaction, and a corresponding alkoxy substituent is introduced to obtain a compound of the formula III;
- Step (2) a compound of the formula III is subjected to a ring closure reaction under heating to obtain a compound of the formula I;
- the reaction conditions in which the compound of the formula II is introduced into the corresponding alkoxy substituent by a nucleophilic substitution reaction are conventionally selected by those skilled in the art.
- the nucleophilic substitution reaction can be carried out under basic or neutral conditions.
- the base is well known to those skilled in the art and may, for example, be potassium carbonate, sodium carbonate, sodium hydride, sodium hydroxide, triethylamine or the like.
- reaction conditions of the compound of the formula III and the ring-closing reaction of hydrazine under heating are conventionally selected by those skilled in the art.
- the reaction can be carried out under heating under alkaline or neutral conditions.
- the base is well known to those skilled in the art and may, for example, be potassium carbonate, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide, triethylamine or the like.
- the heating conditions are well known to those skilled in the art and may, for example, be heated to 120-180 ° C or heated with microwaves.
- the quinazoline compound of the present invention includes a physiologically acceptable salt thereof, and a physiologically acceptable salt of the quinazoline compound can be produced by dissolving the compound in an alcohol solution saturated with a corresponding acid,
- a physiologically acceptable salt of the quinazoline compound can be produced by dissolving the compound in an alcohol solution saturated with a corresponding acid,
- the quinazoline compound of the present invention is dissolved in a saturated methanol solution of HCl, stirred at room temperature for 3 hours, and the solvent is evaporated to dryness to give the corresponding hydrochloride.
- the present invention also provides a pharmaceutical composition for anti-flavivirus, particularly a pharmaceutical composition for treating dengue virus and hepatitis C virus, which comprises a therapeutically effective amount of the formula I
- a quinazoline compound and a pharmaceutically acceptable carrier are shown.
- the pharmaceutically acceptable carrier refers to a conventional pharmaceutical carrier in the pharmaceutical field, such as: a diluent such as water; a filler such as starch, sucrose, etc.; a binder such as a cellulose derivative, an alginate, gelatin, Polyvinylpyrrolidone; wetting agent such as glycerin; disintegrants such as agar, calcium carbonate and sodium hydrogencarbonate; absorption enhancers such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and soap Clay; lubricants such as talc, calcium stearate, magnesium stearate, polyethylene glycol, etc.
- other adjuvants such as flavoring agents, sweeteners and the like may also be added to the composition.
- the quinazoline compound of the present invention can be administered to a patient in need of such treatment in the form of a composition by oral, rectal or parenteral administration.
- a composition by oral, rectal or parenteral administration.
- it can be made into a conventional solid system.
- the quinazoline compound of the present invention or a physiologically acceptable salt thereof has been subjected to biological experiments on the inhibitory activity of the Flaviviridae virus (dengue virus and hepatitis C virus) on a cell model, and it has a very strong yellow color.
- Viral virus inhibitory activity which can be used for the preparation of a medicament for treating a Flaviviridae virus infection, particularly a disease caused by a dengue virus and a hepatitis C virus infection.
- Example 6 Preparation of Compound Yhhu-1036 (5-tert-Butoxy-2,4-diaminoquinazoline) It was prepared in the same manner as in Example 1 except that 4-tert-butanol was used instead of methanol.
- Example 8 Preparation of Compound Yhhu-1046 (5-Benzyloxy)-2,4,-diaminoquinazoline) The same procedure as in Example 1 was carried out except that benzyl alcohol was used instead of methanol.
- Example 9 Preparation of Compound Yhhu-1053 (5-(3-Chlorophenoxy)-2,4-diaminoquinazoline) The same as Example 2 except that 3-chlorophenol was used instead of 4-chlorophenol. Method of preparation.
- Example 10 Preparation of Compound Yhhu-1056 (5-cyclopentanyloxy-2,4-diaminoquinazoline) The same procedure as in Example 1 was carried out except that cyclopentanol was used instead of methanol.
- Huh7.5.1-HCV assay Huh7.5.1 cells are currently the only cell model capable of supporting HCV virus infection in vitro, capable of being infected with HCV virus in vitro and producing infectious progeny virus. J399EM is a full-length HCV mutant transfected with EGFP, which can produce a virus with the same infectious ability as JFH-1 wild type, and can directly observe NS5A-EGFP fusion protein in infected cells by inserting EGFP coding sequence in NS5A region. Fluorescence. In this experiment, Huh7.5.1 cells were seeded in 96-well plates and cultured at 37 °C, 5% CO 2 for 24 h.
- the J399EM virus supernatant (moi-0.1) was infected with Huh7.5.1 cells, and the uninfected cell control wells were set. After 8 hours of infection, the cells were washed with PBS. Different concentrations of samples were added to Huh7.5.1 cells infected with J399EM virus, double wells were set for each concentration, and no sample control wells were set. The test samples were diluted in six concentrations, added separately, and continued to culture for 72 hours. After 72 hours of sample processing, the excitation wavelength was 488 nm and the emission wavelength was 516 nm on the fluorescence microplate reader. The relative fluorescence intensity (RFU) was read to test the inhibition of HCV by the sample. The HCV virus inhibition rate was calculated according to the formula.
- the test results show that the compound of the present invention has a strong anti-invasive activity against type II dengue virus and hepatitis C virus.
- the inhibitory effect of the compound on the copy number of the virus in the DHK2-infected BHK culture supernatant directly reflects the inhibitory effect of the compound on the progeny virus production.
- the inhibitory effect of the compound on intracellular replication of HCV virus can be visually detected by fluorescence.
- the HCV virus-infected Huh7.5.1 cell model can maximize the infection and replication process of hepatitis C virus in vivo.
- Control compounds such as mycophenolic acid and the clinical broad-spectrum antiviral drug ribavirin (Ribavirin) have a half effective inhibitory concentration of 1.25 ⁇ and 20 ⁇ for HCV virus in vitro. Since the type II dengue virus and the hepatitis C virus belong to the Flaviviridae family, the compounds of the present invention have excellent antiviral inhibitory activity against the Flaviviridae virus.
- the compounds according to the invention have excellent inhibitory activity against Flaviviridae viruses.
- the compounds according to the present invention can be used for the preparation of excellent drugs for the treatment of Flaviviridae viruses, particularly hepatitis C virus and dengue virus.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11847845.2A EP2649999A4 (en) | 2010-12-09 | 2011-12-02 | USE OF QUINAZOLIN COMPOUND IN THE PREPARATION OF ANTI-FLAVIVIRUS MEDICINE |
US13/992,870 US9133138B2 (en) | 2010-12-09 | 2011-12-02 | Use of a quinazoline compound in preparing a medicament against flaviviridae virus |
JP2013542355A JP5711822B2 (ja) | 2010-12-09 | 2011-12-02 | ラビウイルス科ウイルスの治療薬の調製におけるキナゾリン系化合物の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010581618.3A CN102552271B (zh) | 2010-12-09 | 2010-12-09 | 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途 |
CN201010581618.3 | 2010-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012075908A1 true WO2012075908A1 (zh) | 2012-06-14 |
Family
ID=46206615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/083357 WO2012075908A1 (zh) | 2010-12-09 | 2011-12-02 | 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9133138B2 (zh) |
EP (1) | EP2649999A4 (zh) |
JP (1) | JP5711822B2 (zh) |
CN (1) | CN102552271B (zh) |
WO (1) | WO2012075908A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014154682A1 (en) * | 2013-03-25 | 2014-10-02 | Katholieke Universiteit Leuven | Novel viral replication inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108578410B (zh) * | 2018-03-14 | 2020-12-22 | 南方医科大学 | 一种八氢喹唑啉-5-酮衍生物在作为登革热病毒抑制剂上的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018980A1 (en) * | 1993-02-18 | 1994-09-01 | Fmc Corporation | Insecticidal substituted-2,4-diaminoquinazolines |
WO2007070556A2 (en) * | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(6-membered aromatic ring)-amido anti-viral compounds |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR007857A1 (es) * | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
CA2338328A1 (en) * | 1998-07-21 | 2000-02-03 | Thomas Jefferson University | Small molecule inhibitors of bcl-2 proteins |
JP3018185B1 (ja) * | 1999-02-12 | 2000-03-13 | 工業技術院長 | キナゾリン誘導体又はその塩の製造方法 |
CA2569763C (en) * | 2004-06-08 | 2013-03-12 | Decode Chemistry, Inc. | 2,4-diaminoquinazolines for spinal muscular atrophy |
WO2006002422A2 (en) * | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
JP2008543888A (ja) * | 2005-06-24 | 2008-12-04 | ギリアード サイエンシーズ, インコーポレイテッド | ピリド(3,2−d)ピリミジン、およびC型肝炎を治療するのに有用な医薬組成物 |
GB0520475D0 (en) * | 2005-10-07 | 2005-11-16 | Arrow Therapeutics Ltd | Chemical compounds |
JP2009523163A (ja) * | 2006-01-11 | 2009-06-18 | アロー セラピューティクス リミテッド | 抗ウイルス剤として使用するためのトリアゾロアニリノピリミジン誘導体 |
US8518960B2 (en) * | 2007-05-23 | 2013-08-27 | Siga Technologies, Inc. | Antiviral drugs for treatment or prevention of dengue infection |
-
2010
- 2010-12-09 CN CN201010581618.3A patent/CN102552271B/zh not_active Expired - Fee Related
-
2011
- 2011-12-02 JP JP2013542355A patent/JP5711822B2/ja not_active Expired - Fee Related
- 2011-12-02 US US13/992,870 patent/US9133138B2/en not_active Expired - Fee Related
- 2011-12-02 EP EP11847845.2A patent/EP2649999A4/en not_active Withdrawn
- 2011-12-02 WO PCT/CN2011/083357 patent/WO2012075908A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018980A1 (en) * | 1993-02-18 | 1994-09-01 | Fmc Corporation | Insecticidal substituted-2,4-diaminoquinazolines |
WO2007070556A2 (en) * | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(6-membered aromatic ring)-amido anti-viral compounds |
Non-Patent Citations (1)
Title |
---|
See also references of EP2649999A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014154682A1 (en) * | 2013-03-25 | 2014-10-02 | Katholieke Universiteit Leuven | Novel viral replication inhibitors |
CN105283451A (zh) * | 2013-03-25 | 2016-01-27 | 鲁汶天主教大学 | 新的病毒复制抑制剂 |
JP2016520537A (ja) * | 2013-03-25 | 2016-07-14 | カトリック ユニヴェルシテット ルーヴェン | 新規のウイルス複製阻害剤 |
TWI639583B (zh) * | 2013-03-25 | 2018-11-01 | 比利時魯汶大學 | 新穎病毒複製抑制劑 |
US10633378B2 (en) | 2013-03-25 | 2020-04-28 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Viral replication inhibitors |
CN105283451B (zh) * | 2013-03-25 | 2021-01-26 | 鲁汶天主教大学 | 新的病毒复制抑制剂 |
US11566025B2 (en) | 2013-03-25 | 2023-01-31 | Katholieke Universiteit Leuven | Viral replication inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP2649999A4 (en) | 2014-06-04 |
JP2014502277A (ja) | 2014-01-30 |
CN102552271A (zh) | 2012-07-11 |
CN102552271B (zh) | 2014-08-06 |
US20130261139A1 (en) | 2013-10-03 |
US9133138B2 (en) | 2015-09-15 |
EP2649999A1 (en) | 2013-10-16 |
JP5711822B2 (ja) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105001225B (zh) | 脂质合成的杂环调节剂 | |
CN104822267B (zh) | 乙型肝炎病毒共价闭合环状dna形成的抑制剂及其使用方法 | |
JP5436864B2 (ja) | Vx−950を含む共結晶体およびそれを含む医薬組成物 | |
Ching et al. | Trisubstituted thieno [3, 2-b] pyrrole 5-carboxamides as potent inhibitors of alphaviruses | |
Deng et al. | Inhibition of enterovirus 71 by adenosine analog NITD008 | |
CN102843909A (zh) | 丙型肝炎病毒抑制剂 | |
CN101247807A (zh) | 噻唑化合物及使用方法 | |
JP5443360B2 (ja) | 共結晶体およびそれを含む医薬組成物 | |
TW201026676A (en) | A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds | |
WO2007038425A2 (en) | Anti-viral compouinds | |
CN110177551A (zh) | 脂质合成的杂环调节剂 | |
CN106883280A (zh) | 一种前药、其制备方法、药物组合物及其用途 | |
Boguszewska-Chachulska et al. | Searching for a new anti-HCV therapy: synthesis and properties of tropolone derivatives | |
CN106029060A (zh) | 哌啶和哌啶衍生物及其在治疗病毒感染和癌症中的用途 | |
Han et al. | Identification and structure–activity relationships of diarylhydrazides as novel potent and selective human enterovirus inhibitors | |
Metwally et al. | Novel fluorinated pyrazolo [1, 5-a] pyrimidines: In a way from synthesis and docking studies to biological evaluation | |
CN103097370A (zh) | 用于治疗丙型肝炎的苯并呋喃衍生物 | |
WO2012075908A1 (zh) | 一类喹唑啉类化合物在制备抗黄病毒科病毒的药物中的用途 | |
CN106892920A (zh) | 苦豆碱衍生物、其制备方法及用途 | |
CN108129366B (zh) | 抗病毒化合物、制备方法及其用途 | |
CN104610272B (zh) | 环状黄酮或异黄酮类化合物及其用途 | |
CN110526843A (zh) | 抑制钙/钙调蛋白依赖性蛋白激酶ⅱ的化合物及其应用 | |
JP2008546837A (ja) | 非ヌクレオシド逆転写酵素阻害剤 | |
CN108349907B (zh) | 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用 | |
CN114805141A (zh) | 4-胍基苯甲酸芳基酯类化合物及其在抗SARS-CoV-2病毒中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11847845 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013542355 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13992870 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011847845 Country of ref document: EP |